10 Stocks That Tanked: Why Larry Robbins’ Top Picks Are Struggling in 2026
Larry Robbins is the founder, CEO, and portfolio manager of Glenview Capital Management, a New York-based hedge fund he launched in 2000.
Myriad Genetics Inc (MYGN)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | 125,000,000 | $122,875,000 | 2.44% | ||
| 2. | Millennium Management Israel Englander | 6,668,817 | $30,009,676 | -1% | 0.01% |
| 3. | Glenview Capital Larry Robbins | 5,411,978 | $24,353,901 | +18% | 0.61% |
| 4. | D E Shaw D. E. Shaw | 4,499,724 | $20,248,758 | -1% | 0.01% |
| 5. | AQR Capital Management Cliff Asness | 1,912,296 | $8,605,334 | +3% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $3.69 | 7,500 | $27,637.50 | 97,441 | 2026-05-14 | Filing | |
| $5.00 | 40,000 | $199,844.00 | 493,104 | 2026-03-09 | Filing | |
| $4.66 | 48,000 | $223,728.00 | 281,951 | 2026-02-27 | Filing | |
| $4.80 | 50,407 | $242,104.82 | 233,951 | 2026-02-26 | Filing | |
| $4.74 | 6,100 | $28,889.60 | 183,544 | 2026-02-25 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $22.93 | 15,000 | $343,950.00 | 962,378 | 2024-10-11 | Filing | |
| $26.72 | 15,000 | $400,800.00 | 977,378 | 2024-09-11 | Filing | |
| $26.17 | 2,100 | $54,961.20 | 108,013 | 2024-09-11 | Filing | |
| $27.05 | 10,000 | $270,520.00 | 121,648 | 2024-09-09 | Filing | |
| $27.95 | 46,012 | $1,285,851.35 | 42,533 | 2024-09-03 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 8,889,644 | $40,003,403 | 0% | |
| 2. | 4,424,027 | $19,908,122 | 0% | |
| 3. | 3,924,525 | $17,660,363 | 0% | |
| 4. | 3,168,742 | $14,259,341 | 0% | |
| 5. | 2,582,231 | $11,620,040 | 0% |
News See All
Myriad Genetics, Inc. (NASDAQ:MYGN) Q1 2026 Earnings Call Transcript
Operator: Good day and thank you for standing by. Welcome to the Myriad Genetics First Quarter 2026 Earnings Call. [Operator Instructions] Please be advised that today's conference is being recorded.
Myriad Genetics, Inc. (NASDAQ:MYGN) Q4 2025 Earnings Call Transcript
Operator: Good day and thank you for standing by. Welcome to the Myriad Genetics Fourth Quarter and Full Year 2025 Earnings Call.
Myriad Genetics, Inc. (NASDAQ:MYGN) Q3 2025 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Myriad Genetics' Third Quarter 2025 Earnings Conference Call.
TD Cowen Maintained a Hold Rating on Myriad Genetics (MYGN)
Myriad Genetics, Inc. (NASDAQ:MYGN) is one of the Best 52-Week Low Penny Stocks to Buy Now. On August 5, Daniel Brennan from TD Cowen maintained a Hold rating on Myriad Genetics, Inc.
10 Best 52-Week Low Penny Stocks to Buy Now
On March 26, Gabelli released its Small Cap Outlook for 2025 and beyond.
Myriad Genetics, Inc. (NASDAQ:MYGN) Q2 2025 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Myriad Genetics Second Quarter 2025 Financial Earnings Conference Call.
Billionaire Larry Robbins' 10 Stock Picks with Huge Upside Potential
Larry Robbins is an American hedge fund manager and philanthropist who founded Glenview Capital Management in 2000. The firm manages capital for investors across a range of private investment funds.
Myriad Genetics, Inc. (NASDAQ:MYGN) Q1 2025 Earnings Call Transcript
Operator: Welcome to the Myriad Genetics First Quarter 2025 Financial Earnings Conference Call.
Hedge Fund Resource Center